Ikena Oncology IKNA 深 沪
已收盘 07-25 16:00:00 美东时间
1.43
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.43
- 总市值 6900.91万
- 52周最高 23.28
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 11.6484
- 委 比 0.00%
- 总股本 4825.81万
- 历史最高 451.32
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.6484
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ikena Oncology Completes Merger, Becomes ImageneBio, Inc.
An update from Ikena Oncology ( ($IKNA) ) is now available. On July 25, 2025, I...
07-29 18:28
创响生物宣布完成与Ikena Oncology反向并购交易
7月28日，创响生物（Inmagene Biopharmaceuticals）宣布完成与Ikena Oncology, Inc.的反向并购交易。合并后的公司正式...
07-28 19:18
Ikena Oncology Q2 EPS $(0.06) Beats $(0.14) Estimate
Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is a 78.57 percent increase over losses of $(0.28) per share from
07-25 05:46
Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO
Ikena Oncology (NASDAQ:IKNA) and Inmagene Biopharmaceuticals on Wednesday announced the appointment of Kristin Yarema, Ph.D. as chief executive officer of ImageneBio, of the combined company after the...
07-23 21:43
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Ikena Oncology and Inmagene Biopharmaceuticals announced the appointment of Kristin Yarema, Ph.D., as CEO of the combined company, ImageneBio, following their merger. The merger, approved by shareholders, is expected to close by late July 2025 with a $75 million private placement, listing on Nasdaq under "IMA." Yarema brings over 20 years of experience in biotech leadership, previously serving as CEO of Poseida Therapeutics and holding senior rol...
07-23 13:00
Ikena Oncology Announces Merger with Inmagene
Ikena Oncology ( ($IKNA) ) has shared an announcement. On December 23, 2024, Ik...
07-23 04:48
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Ikena Oncology and Inmagene Biopharmaceuticals completed their merger, with the combined company renaming to ImageneBio (ticker: IMA) and trading on Nasdaq. Ikena executed a 1-for-12 reverse stock split, reducing shares from ~48.2M to ~4M, effective late July. Inmagene focuses on immunological/inflammatory diseases, with IMG-007 showing promise in clinical trials. Ikena specializes in cancer therapies. The merger and financing are expected to clo...
07-15 20:15
Ikena Oncology Merger Recommended by Shareholder Services
Ikena Oncology ( ($IKNA) ) has provided an announcement. On July 11, 2025, Iken...
07-11 20:58
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
Ikena Oncology announced that ISS and Glass Lewis recommend stockholders vote FOR the issuance of shares in connection with the proposed merger with Inmagene Biopharmaceuticals. Inmagene is developing IMG-007, a monoclonal antibody for immunological and inflammatory diseases. The merger proposal is part of the upcoming Annual Meeting of Stockholders on July 15, 2025. CEO Mark Manfredi commented on the potential of IMG-007 and encouraged sharehold...
07-11 12:00
Ikena Oncology: Inmagene Begins Phase 2b Study for IMG-007
Ikena Oncology ( ($IKNA) ) just unveiled an announcement. On July 1, 2025, Inma...
07-02 04:52
